Health technology assessment : HTA
-
Health Technol Assess · Nov 2011
ReviewInsulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world. There is a strong association of NAFLD with insulin resistance and, hence, insulin sensitisers have been tried. This systematic review examined the clinical effectiveness of insulin sensitisers in patients with NAFLD, to help decide whether or not a trial or trials of the insulin sensitisers was necessary and also to explore whether or not non-invasive alternatives to liver biopsy were available that could be used in a large trial of the insulin sensitisers. ⋯ The National Institute for Health Research Health Technology Assessment programme.